Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)
US11339215B2 · kind B2 · utility
0Cited by
55References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2019 |
| Grant date | May 24, 2022 |
| Priority date | — |
| Expiry date | Sep 13, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.